ABSI biotech catalysts & pipeline

ABSCI CORP · Data as of 2026-10-25

Upcoming catalysts

ABS-201 — Interim data

2H 2026

2H 2026: Expected 13-week interim PoC readout

Source filing

ABS-201 — Topline data

Early 2027

Early 2027: Expected 26-week topline PoC readout

Source filing

ABS-201 — Interim data

H2 2027

With the safety, tolerability, and PK data generated in the ongoing HEADLINE trial, Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar